Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial

IMPORTANCE: SB11 and reference ranibizumab (RBZ) are monoclonal anti–vascular endothelial growth factor (VEGF)–A antibodies approved for the treatment of neovascular age-related macular degeneration (nAMD) and other retinal diseases. The association of ranibizumab immunogenicity and treatment outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Bressler, Neil M., Kim, Taehyung, Oh, Inkyung, Russo, Paola, Kim, Mercy Yeeun, Woo, Se Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857301/
https://www.ncbi.nlm.nih.gov/pubmed/36520462
http://dx.doi.org/10.1001/jamaophthalmol.2022.5403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857301/
https://www.ncbi.nlm.nih.gov/pubmed/36520462
http://dx.doi.org/10.1001/jamaophthalmol.2022.5403

Ejemplares similares